JP2018033454A5 - - Google Patents

Download PDF

Info

Publication number
JP2018033454A5
JP2018033454A5 JP2017161826A JP2017161826A JP2018033454A5 JP 2018033454 A5 JP2018033454 A5 JP 2018033454A5 JP 2017161826 A JP2017161826 A JP 2017161826A JP 2017161826 A JP2017161826 A JP 2017161826A JP 2018033454 A5 JP2018033454 A5 JP 2018033454A5
Authority
JP
Japan
Prior art keywords
seq
humanized anti
amino acid
acid sequence
htfr antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017161826A
Other languages
English (en)
Japanese (ja)
Other versions
JP6993814B2 (ja
JP2018033454A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018033454A publication Critical patent/JP2018033454A/ja
Publication of JP2018033454A5 publication Critical patent/JP2018033454A5/ja
Priority to JP2021200504A priority Critical patent/JP7232889B2/ja
Application granted granted Critical
Publication of JP6993814B2 publication Critical patent/JP6993814B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017161826A 2016-08-25 2017-08-25 抗体融合蛋白質の製造方法 Active JP6993814B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021200504A JP7232889B2 (ja) 2016-08-25 2021-12-10 抗体融合蛋白質の製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016164901 2016-08-25
JP2016164901 2016-08-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021200504A Division JP7232889B2 (ja) 2016-08-25 2021-12-10 抗体融合蛋白質の製造方法

Publications (3)

Publication Number Publication Date
JP2018033454A JP2018033454A (ja) 2018-03-08
JP2018033454A5 true JP2018033454A5 (https=) 2020-06-25
JP6993814B2 JP6993814B2 (ja) 2022-01-14

Family

ID=61246169

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017161826A Active JP6993814B2 (ja) 2016-08-25 2017-08-25 抗体融合蛋白質の製造方法
JP2021200504A Active JP7232889B2 (ja) 2016-08-25 2021-12-10 抗体融合蛋白質の製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021200504A Active JP7232889B2 (ja) 2016-08-25 2021-12-10 抗体融合蛋白質の製造方法

Country Status (11)

Country Link
US (1) US11512135B2 (https=)
EP (1) EP3505538B1 (https=)
JP (2) JP6993814B2 (https=)
KR (1) KR102318480B1 (https=)
CN (1) CN109641971B (https=)
AU (1) AU2017316955B2 (https=)
BR (1) BR112019003622A2 (https=)
CA (1) CA3034589A1 (https=)
MX (1) MX389073B (https=)
SG (1) SG11201901495YA (https=)
WO (1) WO2018038243A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI769982B (zh) 2015-06-24 2022-07-11 日商Jcr製藥股份有限公司 通過血腦障壁之抗人類運鐵蛋白受體抗體
US11130815B2 (en) 2015-06-24 2021-09-28 Jcr Pharmaceuticals Co., Ltd. Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody
TWI761413B (zh) 2016-12-26 2022-04-21 日商Jcr製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
AU2017385274B2 (en) 2016-12-26 2024-02-22 Jcr Pharmaceuticals Co., Ltd. Fusion protein including BDNF
KR102655498B1 (ko) 2017-09-07 2024-04-11 제이씨알 파마 가부시키가이샤 수성 의약 조성물
AU2018345303B2 (en) 2017-10-02 2025-09-18 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
AU2019215782A1 (en) * 2018-02-05 2020-07-16 Jcr Pharmaceuticals Co., Ltd. Method for delivering drug to muscle
EP3560945A1 (en) * 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
WO2019224660A1 (ja) * 2018-05-24 2019-11-28 HOYA Technosurgical株式会社 吸着剤の生産方法
KR102692543B1 (ko) * 2018-10-26 2024-08-07 재단법인 목암생명과학연구소 Ids를 포함하는 융합 단백질 및 이의 용도
PE20231931A1 (es) 2020-10-14 2023-12-01 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas
TW202342542A (zh) * 2020-12-23 2023-11-01 大陸商廣東菲鵬製藥股份有限公司 抗pd-l1抗體、編碼其的核酸、包含其的載體、細胞、藥物組合物及其用途
EP4291246A4 (en) * 2021-02-11 2024-12-11 Denali Therapeutics Inc. ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF
CN116917493A (zh) 2021-03-09 2023-10-20 Jcr制药股份有限公司 抗体-溶酶体酶融合蛋白的制造方法
TW202334428A (zh) * 2021-12-28 2023-09-01 日商Jcr製藥股份有限公司 用於安全的基因治療之抗轉鐵蛋白受體抗體與具有生理活性的蛋白質之融合蛋白質
EP4534677A1 (en) * 2022-07-08 2025-04-09 JCR Pharmaceuticals Co., Ltd. Nuecleic acid molecule, vector, recombinant cells, and drug for treating central nervous system diseases
TW202542190A (zh) 2023-12-20 2025-11-01 美商戴納立製藥公司 包含酸性α—葡萄糖苷酶之融合蛋白及其方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1871252A (zh) * 2003-09-05 2006-11-29 Gtc生物治疗学公司 在转基因哺乳动物奶中生产融合蛋白的方法
US20050100965A1 (en) * 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
SG158150A1 (en) * 2004-12-21 2010-01-29 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses
WO2008068879A1 (en) 2006-12-06 2008-06-12 Jcr Pharmaceuticals Co., Ltd. Method for production of human erythropoietin
CN101622274A (zh) * 2006-12-12 2010-01-06 比奥雷克西斯药物公司 转铁蛋白融合蛋白库
JP2009273427A (ja) 2008-05-16 2009-11-26 Jcr Pharmaceuticals Co Ltd 組換え体ヒトfshの製造方法
EP2350130B1 (en) * 2008-10-31 2018-10-03 Wyeth LLC Purification of acidic proteins using ceramic hydroxyapatite chromatography
JP2013507131A (ja) * 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Cnsにおけるイズロン酸2−スルファターゼ活性を増加させるための方法および組成物
JP6018572B2 (ja) 2011-01-25 2016-11-02 Jcrファーマ株式会社 組換えヒトイズロン酸−2−スルファターゼの製造方法
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
WO2013078562A2 (en) * 2011-12-01 2013-06-06 Angiochem Inc. Targeted enzyme compounds and uses thereof
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
WO2014016873A1 (en) * 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
US9994641B2 (en) 2013-12-25 2018-06-12 Jcr Pharmaceuticals Co., Ltd. Anti-human transferrin receptor antibody that passes through blood-brain barrier
EP3214172B1 (en) 2014-10-31 2019-02-13 JCR Pharmaceuticals CO., LTD. Method for producing remcombinant human dnasei
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins

Similar Documents

Publication Publication Date Title
JP2018033454A5 (https=)
JP2017176174A5 (https=)
JP2010515717A5 (https=)
JP2019524645A5 (https=)
JP2012507294A5 (https=)
PE20090769A1 (es) Proteinas de union a antigenos que se unen a par-2
JP2010502207A5 (https=)
EA201291243A1 (ru) Антитела против респираторно-синцитиального вируса (рсв) и способы их применения
FI4074331T3 (fi) Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
RU2015147300A (ru) Гуманизированные антитела к cxcr5, их производные и их применение
JP2012025737A5 (https=)
JP2012025766A5 (https=)
JP2018530331A5 (https=)
JP2012511913A5 (https=)
JP2013172734A5 (https=)
JP2010521147A5 (https=)
JP2015212284A5 (https=)
JP2015527366A5 (https=)
WO2008114149A3 (en) Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains
RU2021134101A (ru) Модифицированная j-цепь
JP2018504907A5 (https=)
WO2016207304A8 (en) Monoclonal anti-il-1racp antibodies
JP2018537415A5 (https=)
FI3596125T3 (fi) Anti-PAR2-vasta-aineita ja niiden käyttöjä
JP2013539454A5 (https=)